Back to search

Article

Palbociclib interferes with replication origin firing in a pRb independent manner

2022-09-22

Abstract excerpt

Over the last decade, CDK4/6 inhibitors (palbociclib, ribociclib and abemaciclib) have emerged as promising anticancer drugs. Numerous studies have demonstrated that CDK4/6 inhibitors efficiently block the pRb-E2F pathway and induce cell cycle arrest in pRb-proficient cells. Based on these studies, the inhibitors have been approved by the FDA for treatment of advanced hormonal receptor (HR) positive breast cancers...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cdf7e974-8e71-5531-9ff4-dcfcd297cac9
DOI
10.1101/2022.09.21.508850
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Palbociclib interferes with replication origin firing in a pRb independent mannerDOI 10.1101/2022.09.21.508850
Select a neighboring publication to make it the new centre.